Form 4: BIO-TECHNE CEO Kim Kelderman Reports Equity Changes
Insider Transaction Report
BIO-TECHNE CEO Kim Kelderman reported recent equity transactions, including the vesting of restricted stock units, a tax-related disposition, and the acquisition of new performance-based and time-based equity awards.
Summary
- BIO-TECHNE CEO Kim Kelderman reported equity transactions on August 15, 2025.
- Acquired 8,543 shares of common stock through the vesting of restricted stock units at a price of $0.
- Disposed of 4,305 shares of common stock at $53.6 per share, primarily for tax withholding related to the vesting.
- Following these transactions, beneficial ownership of common stock stands at 50,968 shares.
- Received new grants including 70,708 performance restricted stock units, 35,354 restricted stock units, and 90,441 stock options with an exercise price of $53.6.
- Holds a substantial portfolio of unvested stock options and restricted stock units, with vesting schedules and performance conditions extending through various dates up to August 15, 2035.
Sentiment
Score: 7
Explanation: The filing reflects routine executive compensation activities, including the vesting of existing awards and the grant of new performance-based and time-based equity, which aligns the CEO's interests with long-term shareholder value. The disposition was for tax purposes, a common occurrence.
Positives
- The CEO's continued accumulation of equity through new grants and vesting indicates strong alignment with shareholder interests.
- New grants of performance-based awards (70,708 Performance RSUs, 23,881 Performance Stock Options, 25,945 Performance Stock Options, 51,261 Performance RSUs) incentivize long-term company performance.
Negatives
- Disposition of 4,305 shares, even if for tax purposes, reduces the CEO's direct common stock ownership.
Risks
- Performance-based awards are contingent on achieving specific company goals, introducing uncertainty regarding their ultimate value and vesting.
- Future fluctuations in the company's stock price could impact the value of unexercised options and unvested restricted stock units.
Future Outlook
The filing details future vesting schedules for the CEO's equity awards, indicating a long-term incentive structure tied to company performance and continued service through various dates up to 2035.
Industry Context
This Form 4 filing is specific to an insider's equity transactions and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: Increased alignment of the CEO's interests with long-term shareholder value through equity compensation, incentivizing sustained performance.
Next Steps
- Continued vesting of various stock options and restricted stock units on specified future dates.
- Achievement of performance goals for performance-based equity awards to ensure full vesting.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Vesting date for a portion of stock options (29,391 tranche). |
| 11/01/2024 | Vesting date for a portion of stock options (38,252 tranche). |
| 02/01/2025 | Vesting date for a portion of stock options (51,890 tranche). |
| 08/15/2025 | Transaction date for common stock acquisition/disposition; Vesting date for 8,543 restricted stock units and a portion of stock options (29,391 and 69,061 tranches). |
| 08/19/2025 | Filing signature date. |
| 11/01/2025 | Vesting date for a portion of stock options (38,252 tranche). |
| 02/01/2026 | Vesting date for a portion of stock options (51,890 tranche). |
| 08/07/2026 | Expiration date for stock options with exercise price $47.6. |
| 08/15/2026 | Vesting date for performance restricted stock units (8,873 and 9,423 tranches), performance stock options (23,881 and 25,945 tranches), restricted stock units (8,543 and 35,354 tranches), and stock options (29,391, 69,061, and 90,441 tranches). |
| 11/01/2026 | Vesting date for a portion of stock options (38,252 tranche). |
| 02/01/2027 | Vesting date for a portion of stock options (51,890 tranche). |
| 08/05/2027 | Expiration date for stock options with exercise price $66.97. |
| 08/15/2027 | Vesting date for performance restricted stock units (51,261 tranche), restricted stock units (8,544 and 35,354 tranches), and stock options (29,391, 69,061, and 90,441 tranches). |
| 11/01/2027 | Vesting date for a portion of stock options (38,252 tranche). |
| 02/01/2028 | Vesting date for a portion of stock options (51,890 tranche). |
| 08/06/2028 | Expiration date for stock options with exercise price $120.46. |
| 08/15/2028 | Vesting date for performance restricted stock units (70,708 tranche), restricted stock units (35,354 tranche), and stock options (69,061 and 90,441 tranches). |
| 08/15/2029 | Expiration date for stock options with exercise price $94.52. |
| 08/15/2030 | Expiration date for performance stock options ($84.61) and stock options ($84.61). |
| 11/01/2030 | Expiration date for stock options with exercise price $52.83. |
| 02/01/2031 | Expiration date for performance stock options ($68.54) and stock options ($68.54). |
| 08/15/2034 | Expiration date for stock options with exercise price $74.91. |
| 08/15/2035 | Expiration date for stock options with exercise price $53.6. |
Recommendation
holdThis Form 4 details routine executive compensation activities, including the vesting of equity awards and the grant of new performance-based incentives. It does not present new information that would fundamentally alter the investment thesis for BIO-TECHNE, thus a 'hold' recommendation remains appropriate.
Keywords
BIO-TECHNE, TECH, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, CEO, Equity Compensation, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.